Health Plans | Benefit Protection Embarc Benefit ProtectionSM

Breakthrough, potentially life-changing medicines offer great promise for patients and their families. However, the high prices of the medicines – millions of dollars in some cases – threaten coverage and access by patients who may benefit. Indeed, by 2024, the cost of gene therapies is expected to reach more than $16 billion in the United States. Today, our health services business is introducing Embarc Benefit ProtectionSM a new offering that brings together the health services, medical benefit management and specialty pharmacy expertise of Express Scripts, eviCore, Accredo and CuraScriptSD to make breakthrough medicines more affordable and ensure access for those who need it.

Shielding Payers and Patients

Embarc Benefit Protection addresses a critical need facing the entire health care system, delivering better care, affordability and access. Importantly, consumers will have no out-of-pocket payments related to the cost of the medicine and will receive personalized and expert care to assist them through their health journey.

Those who provide health coverage for millions of Americans, such as employers, health plans and unions, will have the peace of mind that comes from being better protected against the high price shocks associated with new breakthrough therapies. Our intention is to include Luxturna™ (voretigene neparvovec-rzyl), the first FDA-approved prescription gene therapy for people with inherited retinal disease, and Zolgensma® (onasemnogene abeparvovec-xioi), a gene therapy for children under 2 years old with spinal muscular atrophy, in the Embarc Benefit Protection solution. Additional therapies may be added in the future. Like our recent advances with our Patient Assurance ProgramSM and digital health formulary, Embarc Benefit Protection is another great example of what our combined company can do now for our clients and patients. We are leveraging our collective capabilities to deliver on the true promise of modern medicine. No cure should be out of reach of any patient, and they should receive the best quality care.